Cantargia AB (publ) (CANTA.ST) has a MoatMap StockRank of 93/100 based on Quality (77/100), Value (65/100), and Momentum (33/100) factor scores. The current signal is STRONG BUY. Cantargia AB is a biotech company, often speculative and heavily reliant on clinical trial success. This business model does not align with the fund's philosophy of investing in proven 'quality compounders' with 'durable economic moats' and predictable cash flows, avoiding 'turnarounds' or businesses 'hoping for a rescue'.